argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
646.60
+9.04 (1.42%)
At close: Aug 13, 2025, 4:00 PM
645.79
-0.81 (-0.13%)
After-hours: Aug 13, 2025, 5:39 PM EDT
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
$1,951,733
Profits / Employee
$800,749
Market Cap
39.49B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,599 | 451 | 39.29% |
Dec 31, 2023 | 1,148 | 305 | 36.18% |
Dec 31, 2022 | 843 | 193 | 29.69% |
Dec 31, 2021 | 650 | 314 | 93.45% |
Dec 31, 2020 | 336 | 148 | 78.72% |
Dec 31, 2019 | 188 | 83 | 79.05% |
Dec 31, 2018 | 105 | 32 | 43.84% |
Dec 31, 2017 | 73 | 15 | 25.86% |
Dec 31, 2016 | 58 | 17 | 41.46% |
Dec 31, 2015 | 41 | 9 | 28.13% |
Dec 31, 2014 | 32 | 10 | 45.45% |
Dec 31, 2013 | 22 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARGX News
- 1 day ago - argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis - GlobeNewsWire
- 6 days ago - Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts - Seeking Alpha
- 13 days ago - argenx SE (ARGX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update - GlobeNewsWire
- 21 days ago - argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 - GlobeNewsWire
- 6 weeks ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 7 weeks ago - argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 2 months ago - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease - GlobeNewsWire